



(51) International Patent Classification:

A61K 38/02 (2006.01) A61K 47/68 (2017.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2021/040987

(22) International Filing Date:

09 July 2021 (09.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/055,768	23 July 2020 (23.07.2020)	US
63/061,839	06 August 2020 (06.08.2020)	US
63/143,828	30 January 2021 (30.01.2021)	US
63/181,456	29 April 2021 (29.04.2021)	US

(71) Applicant: **DYNE THERAPEUTICS, INC.** [US/US];
830 Winter Street, Waltham, MA 02451 (US).

(72) Inventors: **SUBRAMANIAN, Romesh, R.**; 830 Winter
Street, Waltham, MA 02451 (US). **QATANANI, Mo-**

ammed, T.; 830 Winter Street, Waltham, MA 02451 (US).
WEEDEN, Timothy; 830 Winter Street, Waltham, MA
02451 (US). **DESJARDINS, Cody, A.**; 830 Winter Street,
Waltham, MA 02451 (US). **QUINN, Brendan**; 830 Win-
ter Street, Waltham, MA 02451 (US). **NAJIM, John**; 830
Winter Street, Waltham, MA 02451 (US).

(74) Agent: **YOUNG, Daniel, W.** et al.; Wolf, Greenfield &
Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL
MUSCULAR DYSTROPHY




FIG. 17

(57) Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*